Cosmo Pharmaceuticals (0RGI.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0RGI.L in your mock portfolio yet.
A PE ratio of 55.78 and EPS of 1.31 indicate that Cosmo Pharmaceuticals is profitable but priced at a premium relative to current earnings. This suggests the market is embedding meaningful growth expectations, but without additional revenue and margin data, it is unclear whether fundamentals fully justify the valuation. Profitability exists, yet the high multiple raises questions about risk/reward if growth underdelivers.
At $72.80, Cosmo Pharmaceuticals trades well above its 200-day moving average of $48.12, indicating a strong longer-term uptrend despite a modest 1.3% pullback over the last month. The recent dip looks more like consolidation within an established bullish trend than a structural breakdown. Absent signs of heavy selling or a move below the 200-day average, technicals lean positive.
Alternative data points are mixed to negative: hiring is down 25% month over month and web traffic is extremely low, while LinkedIn followers are relatively robust for a specialized pharma company. The drop in job openings may signal more cautious growth or cost control, which can be prudent but may also indicate a slower expansion phase. Overall, these signals do not strongly support the premium valuation implied by the stock price.
Cosmo Pharmaceuticals shows a strong technical uptrend and positive earnings, but trades at a high valuation multiple that is not clearly supported by the available alternative data signals. The modest recent price pullback and slowdown in hiring temper the otherwise bullish technical picture. Overall, the setup appears balanced between upside from continued execution and downside if growth or pipeline expectations are not met.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started